inclusion criteria: 1. written informed consent prior to performing study procedures. witnessed oral consent will be accepted in order to avoid paper handling. written consent by patient or representatives will be obtained as soon as possible. 2. male or female adult patient ≥18 years of age at time of enrolment. 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr in naso/oropharyngeal swabs or any other relevant specimen in the ongoing covid-19 symptomatic period. alternative test (i.e antigenic tests) are also acceptable as laboratory confirmation if their adequate specificity has been accepted by the sponsor. 4. patients requiring hospitalization for covid-19 without mechanical ventilation (invasive or non-invasive) or high flow oxygen devices and at least one of the following: * radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, ct scan, etc.), or * clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air that requires supplemental oxygen. 5. no more than 7 days between the onset of symptoms (fever or cough) and treatment administration day.

inclusion criteria: 1. written informed consent prior to performing study procedures. witnessed oral consent will be accepted in order to avoid paper handling. written consent by patient or representatives will be obtained as soon as possible. 2. male or female adult patient ≥18 years of age at time of enrolment. 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr in naso/oropharyngeal swabs or any other relevant specimen in the ongoing covid-19 symptomatic period. alternative test (i.e antigenic tests) are also acceptable as laboratory confirmation if their adequate specificity has been accepted by the sponsor. 4. patients requiring hospitalization for covid-19 without mechanical ventilation (invasive or non-invasive) or high flow oxygen devices and at least one of the following: * radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, ct scan, etc.), or * clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air that requires supplemental oxygen. 5. no more than 7 days between the onset of symptoms (fever or cough) and treatment administration day.

inclusion criteria: written informed consent prior to performing study procedures. witnessed oral consent will be accepted in order to avoid paper handling. written consent by patient or representatives will be obtained as soon as possible. male or female adult patient ≥18 years of age at time of enrolment. has laboratory-confirmed sars-cov-2 infection as determined by pcr in naso/oropharyngeal swabs or any other relevant specimen in the ongoing covid-19 symptomatic period. alternative test (i.e antigenic tests) are also acceptable as laboratory confirmation if their adequate specificity has been accepted by the sponsor. patients requiring hospitalization for covid-19 without mechanical ventilation (invasive or non-invasive) or high flow oxygen devices and at least one of the following: radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, ct scan, etc.), or clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air that requires supplemental oxygen. no more than 7 days between the onset of symptoms (fever or cough) and treatment administration day.

inclusion criteria: written informed consent prior to performing study procedures. witnessed oral consent will be accepted in order to avoid paper handling. written consent by patient or representatives will be obtained as soon as possible. male or female adult patient ≥18 years of age at time of enrolment. has laboratory-confirmed sars-cov-2 infection as determined by pcr in naso/oropharyngeal swabs or any other relevant specimen in the ongoing covid-19 symptomatic period. alternative test (i.e antigenic tests) are also acceptable as laboratory confirmation if their adequate specificity has been accepted by the sponsor. patients requiring hospitalization for covid-19 without mechanical ventilation (invasive or non-invasive) or high flow oxygen devices and at least one of the following: radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, ct scan, etc.), or clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air that requires supplemental oxygen. no more than 7 days between the onset of symptoms (fever or cough) and treatment administration day.

inclusion criteria: 1. written informed consent prior to performing study procedures. witnessed oral consent will be accepted in order to avoid paper handling. written consent by patient or representatives will be obtained as soon as possible. 2. male or female adult patient ≥18 years of age at time of enrolment. 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr in naso/oropharyngeal swabs or any other relevant specimen in the ongoing covid-19 symptomatic period. alternative test (i.e antigenic tests) are also acceptable as laboratory confirmation if their adequate specificity has been accepted by the sponsor. 4. patients requiring hospitalization for covid-19 without mechanical ventilation (invasive or non-invasive) or high flow oxygen devices and at least one of the following: - radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, ct scan, etc.), or - clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air that requires supplemental oxygen. 5. no more than 7 days between the onset of symptoms (fever or cough) and treatment administration day.

inclusion criteria: 1. written informed consent prior to performing study procedures. witnessed oral consent will be accepted in order to avoid paper handling. written consent by patient or representatives will be obtained as soon as possible. 2. male or female adult patient ≥18 years of age at time of enrolment. 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr in naso/oropharyngeal swabs or any other relevant specimen in the ongoing covid-19 symptomatic period. alternative test (i.e antigenic tests) are also acceptable as laboratory confirmation if their adequate specificity has been accepted by the sponsor. 4. patients requiring hospitalization for covid-19 without mechanical ventilation (invasive or non-invasive) or high flow oxygen devices and at least one of the following: - radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, ct scan, etc.), or - clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air that requires supplemental oxygen. 5. no more than 7 days between the onset of symptoms (fever or cough) and treatment administration day.

inclusion criteria: 1. written informed consent prior to performing study procedures. witnessed oral consent will be accepted in order to avoid paper handling. written consent by patient or representatives will be obtained as soon as possible. 2. male or female adult patient ≥18 years of age at time of enrolment. 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr in naso/oropharyngeal swabs or any other relevant specimen. 4. patients requiring hospitalization for covid-19 without mechanical ventilation (invasive or non-invasive) or high flow oxygen devices and at least one of the following: - radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, ct scan, etc.), or - clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air that requires supplemental oxygen. 5. no more than 12 days between the onset of symptoms (fever or cough) and treatment administration day.

inclusion criteria: 1. written informed consent prior to performing study procedures. witnessed oral consent will be accepted in order to avoid paper handling. written consent by patient or representatives will be obtained as soon as possible. 2. male or female adult patient ≥18 years of age at time of enrolment. 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr in naso/oropharyngeal swabs or any other relevant specimen. 4. patients requiring hospitalization for covid-19 without mechanical ventilation (invasive or non-invasive) or high flow oxygen devices and at least one of the following: - radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, ct scan, etc.), or - clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air that requires supplemental oxygen. 5. no more than 12 days between the onset of symptoms (fever or cough) and treatment administration day.